Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
暂无分享,去创建一个
J. Wagner | Yang Liu | R. Krishna | S. Stoch | J. Cote | A. Maes | D. Stypinski | Melissa Ali | A. Garg | B. Degroot | S. Li | S. Connolly | S. Stoch | Amit Garg
[1] J. Wagner,et al. Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects , 2011, Journal of clinical pharmacology.
[2] Christopher P Cannon,et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. , 2010, The New England journal of medicine.
[3] L. Benet,et al. Effect of Single‐Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers , 2010, Clinical pharmacology and therapeutics.
[4] D. Dean,et al. Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans , 2010, Drug Metabolism and Disposition.
[5] G. Herman,et al. Multiple Doses of Sitagliptin, a Selective DPP‐4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin , 2009, Journal of clinical pharmacology.
[6] L. V. Van Bortel,et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. , 2009, British journal of clinical pharmacology.
[7] J. Chodakewitz,et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. , 2009, British journal of clinical pharmacology.
[8] Daniel Bloomfield,et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. , 2009, American heart journal.
[9] A. Bergman,et al. Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers , 2009, Journal of clinical pharmacology.
[10] D. Bloomfield,et al. Multiple‐Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.
[11] J. Wagner,et al. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin , 2008, Advances in therapy.
[12] John A Wagner,et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies , 2007, The Lancet.
[13] C. Washington,et al. Ciprofloxacin Prolonged‐Release Tablets Do Not Affect Warfarin Pharmacokinetics and Pharmacodynamics , 2007, Journal of clinical pharmacology.
[14] B. Gertz,et al. Effect of Montelukast on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers , 1999, Journal of clinical pharmacology.
[15] J. Hirsh,et al. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. , 1996, The Journal of laboratory and clinical medicine.
[16] A. Tall. Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.
[17] W. Bartle,et al. Drug interactions with warfarin , 1993, The Medical journal of Australia.
[18] J. Hirsh. Oral anticoagulant drugs. , 1991, The New England journal of medicine.
[19] T B Kirkwood,et al. Calibration of Reference Thromboplastins and Standardisation of the Prothrombin Time Ratio , 1983, Thrombosis and Haemostasis.
[20] A. Mrhar,et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.
[21] Michael Miller. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[22] J. Hirsh,et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.
[23] L. Kaminsky,et al. Human P450 metabolism of warfarin. , 1997, Pharmacology & therapeutics.
[24] T. Aoyama,et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.